BioSpace News Archive

ASLAN Pharmaceuticals announced that an abstract on eblasakimab in Chronic Obstructive Pulmonary Disease has been accepted for a late breaking poster presentation at the American Thoracic Society International Conference 2024.

atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that the first patient has been dosed in Part 2 of Beckley Psytech’s Phase 2a study, evaluating BPL-003 in patients living with Treatment Resistant Depression.

RedHill Biopharma Ltd. announced that the first patient has been enrolled in the Austere environments Consortium for Enhanced Sepsis Outcomes’ U.S. government-supported PROTECT multinational platform trial for early COVID-19 outpatient treatment.

Ipsen, a global specialty-care biopharmaceutical company, presents its sales for the first quarter of 2024.

Net sales amounted to SEK 186.0 million (140.6), corresponding to an increase of 32 percent in SEK and equivalent increase, 32 percent, adjusted for currency effects.

During the first quarter of the year, we continued making excellent progress with our clinical pipeline targeting TNFR2 and FcyRIIB, building on the momentum we generated during a very successful 2023.

Harness Therapeutics, a biotechnology company focused on protein upregulation to develop next generation therapeutics for neurodegenerative diseases, announced the appointment of Ms. Meenu Chhabra Karson as Chair of its Board of Directors.

CSL Vifor and Travere Therapeutics, Inc., announced that the European Commission has granted conditional marketing authorization for FILSPARI for the treatment of adults with primary IgAN with a urine protein excretion ≥1.0 g/day.

Affimed N.V. announced that an abstract presenting preliminary data from the phase 2 combination study of AFM24, its innate cell engager, in combination with atezolizumab, Roche’s checkpoint inhibitor, in patients with EGFR-wildtype non-small cell lung cancer has been accepted for poster presentation at 2024 American Society of Clinical Oncology Annual Meeting.

Atom Bioscience, a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, has begun enrolling patients in the US for in a Phase 2b/3 clinical trial of ABP-671, a novel investigational orally administered URAT1 inhibitor, for the treatment of chronic gout.